

Allergy Immunotherapy Market Set to Surge to \$4.9 Billion by 2033 at a 10.4% CAGR

The global allergy immunotherapy market was valued at \$1.8 billion in 2023 and is projected to reach \$4.9 billion by 2033, growing at a CAGR of 10.4%.

WILMINGTON, DE, UNITED STATES, March 18, 2025 /EINPresswire.com/ --

According to Allied Market Research, the global [allergy immunotherapy market](#) was valued at \$1.8 billion in 2023 and is projected to reach \$4.9 billion by 2033, growing at a CAGR of

10.4% from 2024 to 2033. This growth trajectory underscores the escalating demand for effective allergy treatments worldwide.

Report Insights



Market was valued at
\$1.8 Billion
2023




Projected to reach
\$4.9 Billion
2033



Growing at a CAGR
10.4% From
2024-2033

CAGR 10.4%



Allergy Immunotherapy Market
Report Code: A10241

Allied Market Research
© All right reserved

Allergy Immunotherapy Market Research Report

The global allergy immunotherapy market is poised for substantial growth, driven by the increasing prevalence of allergic disorders and advancements in treatment methodologies. Allergy immunotherapy, also known as desensitization or hypo-sensitization, involves the gradual introduction of specific allergens into a patient's system to reduce sensitivity and alleviate allergic reactions. This treatment is particularly beneficial for individuals who do not respond adequately to conventional allergy medications.

Get Sample PDF Copy: <https://www.alliedmarketresearch.com/request-sample/A10241>

Allergy Immunotherapy Market Growth Factors

Several key factors contribute to the expansion of the allergy immunotherapy market:

- 1. Rising Prevalence of Allergic Disorders:** The incidence of allergies has been on the rise globally, affecting millions of individuals. This surge necessitates effective long-term treatments like immunotherapy to manage and mitigate allergic reactions.
- 2. Advancements in Treatment Options:** Innovations in immunotherapy techniques, such as sublingual immunotherapy (SLIT), have enhanced the safety and convenience of treatments, making them more accessible to patients.
- 3. Increased Awareness and Diagnosis:** Growing awareness about allergic conditions has led to higher diagnosis rates, prompting more individuals to seek effective treatments like

immunotherapy.

4. Favorable Reimbursement Policies: In regions like North America and Europe, supportive healthcare policies and reimbursement structures have facilitated patient access to immunotherapy treatments.

Allergy Immunotherapy Market Segmentation

The allergy immunotherapy market is segmented based on treatment type, allergy type, distribution channel, and region.

1. By Treatment Type:

- Subcutaneous Immunotherapy (SCIT): This traditional method involves regular injections of allergens and has been effective in treating various allergies.
- Sublingual Immunotherapy (SLIT): Administered orally through tablets or drops, SLIT offers a non-invasive alternative to injections, increasing patient compliance.

2. By Allergy Type:

- Allergic Rhinitis: Characterized by nasal inflammation due to allergens, this segment holds a significant share of the market.
- Allergic Asthma: A respiratory condition triggered by allergens, leading to asthma symptoms.
- Others: Includes food allergies, insect venom allergies, and drug allergies, with a growing recognition of these conditions contributing to market expansion.

3. By Distribution Channel:

- Hospital Pharmacies: These establishments play a crucial role in dispensing immunotherapy treatments, given their direct access to healthcare professionals.
- Retail Pharmacies: Provide over-the-counter and prescription allergy treatments to a broad consumer base.
- Online Pharmacies: The rise of e-commerce has led to increased availability of allergy treatments through online platforms, offering convenience to patients.

4. By Region:

- North America: Dominated the global allergy immunotherapy market in 2023, attributed to the high prevalence of allergy conditions and a well-developed healthcare system.
- Europe: Held a significant market share due to high diagnosis rates and supportive healthcare infrastructure.
- Asia-Pacific: Anticipated to witness high growth, driven by rapid modernization, elevated levels of air pollution, and increasing healthcare expenditure.

Have Any Query? Ask Our Experts: <https://www.alliedmarketresearch.com/purchase-enquiry/A10241>

Key Players in the Allergy Immunotherapy Market

Prominent companies operating in the allergy immunotherapy market include:

- ALK-Abelló A/S

- Allergy Therapeutics
- DBV Technologies
- Intrommune Therapeutics
- HAL Allergy B.V.
- LETIPharma
- Circassia
- Allovate, LLC
- Torii Pharmaceutical Co., Ltd
- Stallergenes Greer
- Biomay AG
- Jubliant Pharma
- Merck KGaA

The allergy immunotherapy market is on an upward trajectory, driven by the increasing prevalence of allergic disorders and continuous advancements in treatment options. As awareness grows and more patients seek effective long-term solutions, immunotherapy stands out as a promising approach to managing and potentially mitigating the impact of allergies worldwide.

Procure Complete Report: <https://www.alliedmarketresearch.com/allergy-immunotherapy-market/purchase-options>

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa

Allied Market Research

+ 1800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/795057492>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.